The family-owned German firm's legacy lies in the cardiometabolic space but it has been building a pipeline across a range of neuropsychiatric diseases. The collaboration with Sosei Heptares, which has been sealed with a upfront payment of €25m, will focus on schizophrenia.

Boehringer Ingelheim’s Head of Human Pharma Regions, Timmo Rousku Andersen shares with Scrip glimpses of his life and professional journey including distinct parallels between sports and leadership against the backdrop of the wider commercialization efforts for blockbuster therapy Jardiance.

During a panel at the 2022 BioFuture conference, panelists talked about how digital technology can provide data about drugs and devices on the market or in clinical trials.